J12.82 Insurance Policy Changes

ICD-10 J12.82 is officially defined as "Pneumonia due to coronavirus disease 2019." code J12.82 is referenced in 11 tracked payer policy changes from Aetna, Colorado Medicaid, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code J12.82 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 16, 2026Medium impact
Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)
Aetna considers ribavirin for inhalation medically necessary for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Aetna considers all other indications experimental, investigational, or unproven, including the cationic liposome encapsulated ribavirin spray for the treatment of acute pneumonia. Ribavirin for inhalation is not indicated for use in adults.
Aetna · Identified Aug 15, 2026Medium impact
Respiratory Devices: Incentive Spirometers, Vaporizers and Intermittent Positive Pressure Breathing Machines (CPB 0479, reviewed 2026-07-09)
Aetna's Clinical Policy Bulletin 0479 covers incentive spirometers, vaporizers and intermittent positive pressure breathing (IPPB) machines. Aetna considers incentive spirometers medically necessary as durable medical equipment for post-operative use in members with neuromuscular or chest wall diseases, and IPPB machines medically necessary as durable medical equipment for members with asthma, COPD and other respiratory diseases. Aetna does not cover vaporizers because they are not considered primarily medical in nature, and it considers the SpiroTimer and incentive spirometry or IPPB for all other listed indications experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Remdesivir (Veklury) (CPB 0982, reviewed 2026-01-13)
For commercial medical plans, Aetna considers remdesivir (Veklury) medically necessary for COVID-19 in non-hospitalized, high-risk members when all listed criteria are met. Hospitalized members receiving Veklury for COVID-19 are managed under the inpatient benefit, and the criteria apply only to coverage in the outpatient setting. Aetna considers the combined use of remdesivir and human monoclonal antibodies for COVID-19, and remdesivir for the prevention of COVID-19 in children and adolescents, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Ravulizumab-cwvz (Ultomiris) (CPB 0946, reviewed 2026-08-11)
Aetna considers ravulizumab-cwvz (Ultomiris) medically necessary for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) when the listed criteria are met. Aetna considers concurrent use of ravulizumab-cwvz and eculizumab experimental, investigational, or unproven. Aetna considers ravulizumab-cwvz experimental, investigational, or unproven for other indications, including amyotrophic lateral sclerosis (ALS), aplastic anemia and COVID-19, and notes that this list is not all-inclusive. Precertification is required of all Aetna participating providers and members in applicable plan designs. The policy was last reviewed 08/11/2026 and lists a next review date of 05/27/2027.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.
Aetna · Identified Aug 14, 2026Medium impact
Pulse Oximetry and Capnography for Home Use (CPB 0339, reviewed 2026-05-21)
Aetna covers home pulse oximetry as durable medical equipment for members with chronic lung disease, severe cardiopulmonary disease, or neuromuscular disease involving the muscles of respiration, when the device is used to determine home oxygen liter flow for ambulation, exercise, or sleep, to monitor a person on a home ventilator, for short-term (one month) monitoring when a physician-directed change in home oxygen liter flow is needed, when weaning from home oxygen, or for interstage monitoring of children undergoing the Norwood procedure for hypoplastic left heart syndrome. Capnography (end-tidal carbon dioxide monitoring) is covered for members with congenital central alveolar hypoventilation syndrome. Home pulse oximetry is considered experimental, investigational, or unproven for asthma management, for evaluating and teaching CPAP, for maintenance or continuous monitoring other than for persons on a ventilator, for predicting the need for adenotonsillectomy in children, and when used alone as a screening or testing technique for suspected obstructive sleep apnea.
Aetna · Identified Aug 13, 2026Medium impact
Plerixafor (CPB 0779, reviewed 2026-02-13)
Aetna's policy covers plerixafor (Mozobil or generic plerixafor) for hematopoietic stem cell mobilization when it is given after a granulocyte-colony stimulating factor such as filgrastim, after chemo-mobilization, or as part of a gene therapy protocol, and when it is not used beyond 4 consecutive days or after stem cell harvest or apheresis is complete. Continuation of therapy is considered medically necessary for members who meet the initial selection criteria. Aetna considers plerixafor experimental, investigational or unproven for all other indications, including the conditions listed in the policy such as acute leukemias, sickle cell disease, WHIM syndrome and neutropenia treatment.
Aetna · Identified Aug 12, 2026Medium impact
Crizanlizumab-tmca (Adakveo) (CPB 0964, reviewed 2025-12-09)
Aetna considers Adakveo (crizanlizumab-tmca) medically necessary for reducing the frequency of vaso-occlusive crises in members 16 years of age or older with sickle cell disease, when the member has had at least one vaso-occlusive crisis in the previous 12 months and either has HbSC, HbSβ+, or another genotypic variant of sickle cell disease, or has HbSS or HbSβ0 genotype and has had an inadequate response to, an intolerance of, or a contraindication to hydroxyurea, or will use Adakveo with concurrent hydroxyurea. Continuation is considered medically necessary when the frequency of vaso-occlusive crises has been reduced since starting therapy or has stayed reduced, and Adakveo must be prescribed by or in consultation with a hematologist or sickle cell disease specialist. All other indications are considered experimental, investigational, or unproven, including treatment and prevention of adverse outcomes in COVID-19. This policy covers commercial medical plans, and Medicare criteria are in Medicare Part B Criteria.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)
The February 2022 Health First Colorado provider bulletin (B2200475) covers several changes. Effective February 1, 2022, claims requiring electronic visit verification (EVV) go through pre-payment review, and claims without the needed EVV records may deny with EOB 3054. The bulletin also describes at-home OTC COVID-19 test billing under HCPCS E1399 with modifier U1 from January 15, 2022, requires the ordering provider's NPI on DMEPOS claims effective July 1, 2022, and notes that 24 physician-administered drug codes became subject to prior authorization effective January 18, 2022.
Blue Cross Blue Shield of Wyoming · Identified Jun 19, 2026Medium impact
NEW! Screening for COVID-19 Diagnosis Guidance
BCBS Wyoming has updated COVID-19 diagnostic testing coding guidance with new ICD-10 codes and clarified coverage rules. The policy specifies that asymptomatic and pre-surgical COVID-19 testing is covered when medically appropriate, but not for return-to-work or surveillance purposes.
Blue Cross Blue Shield of Wyoming · Identified Jun 19, 2026Medium impact
NEW COVID Testing & Diagnosis updates
Blue Cross Blue Shield of Wyoming updated COVID-19 diagnosis and testing billing guidance with new codes. The policy clarifies that new COVID-related diagnosis codes J12.82, M35.81, and M35.89 will not waive cost sharing, while U07.1 should still be included for COVID treatment claims.

Watch J12.82

Get one email when a payer policy names J12.82, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code J12.82?

There are 11 tracked policy changes affecting code J12.82, including updates from Aetna, Colorado Medicaid, Blue Cross Blue Shield of Wyoming. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code J12.82?

Payers that have issued tracked updates for code J12.82 include: Aetna, Colorado Medicaid, Blue Cross Blue Shield of Wyoming.

How do I get notified when code J12.82 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code J12.82. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code J12.82?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)

Respiratory Devices: Incentive Spirometers, Vaporizers and Intermittent Positive Pressure Breathing Machines (CPB 0479, reviewed 2026-07-09)

Remdesivir (Veklury) (CPB 0982, reviewed 2026-01-13)

Ravulizumab-cwvz (Ultomiris) (CPB 0946, reviewed 2026-08-11)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

Pulse Oximetry and Capnography for Home Use (CPB 0339, reviewed 2026-05-21)

Plerixafor (CPB 0779, reviewed 2026-02-13)

Crizanlizumab-tmca (Adakveo) (CPB 0964, reviewed 2025-12-09)

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)

NEW! Screening for COVID-19 Diagnosis Guidance

NEW COVID Testing & Diagnosis updates

What insurance policy changes affect code J12.82?

Which payers have updated policy for code J12.82?

How do I get notified when code J12.82 policy changes?

Why do payers change policies for code J12.82?